NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**CONFIDENTIAL**

## Demo Report

**Report Issued** 02/11/2014 12:54
**Last Report Issued** 01/20/2014 13:23

**88888**
Clinical Example Report
Attn: IT Department
200 Welsh Road
Horsham, PA 19044-2208

**Patient Name** 4366SP-POS
**Patient ID** 4366SP-POS
**Chain** 14000175
**Age** Not Given **DOB** Not Given
**Gender** Not Given
**Workorder** 14000175

**Received** 01/20/2014 12:33

---

**Sample ID** 14000175-001
**Matrix** Serum or Plasma
**Patient Name** 4366SP-POS
**Patient ID** 4366SP-POS
**Container Type** Clear vial

**Collect Dt/Tm** Not Given
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|---|---|---|---|---|
| **4366SP Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma** | | | | |
| Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) | | | | |
| Teriflunomide | 50000 | ng/mL | 500 | |

Synonym(s): Aubagio®

Teriflunomide is indicated for the treatment of patients with relapsing forms of multiple sclerosis. It takes approximately 3 months to reach steady-state concentrations.

Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL.

Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE TERIFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and teratogenicity.